Both high-dose intravenous methylprednisolone (IVMP) and tacrolimus effectively reduced symptom severity in patients with ocular myasthenia gravis (OMG) who failed to respond to oral steroids, a study shows. IVMP began to work quickly and more patients on it achieved a clinically meaningful treatment response over six months. “Both IVMP…
News
Repeat cycles of Vyvgart (efgartigimod alfa-fcab) led to consistent clinical improvements among generalized myasthenia gravis (gMG) patients, regardless of whether they were positive for antibodies against the acetylcholine receptor, according to interim findings from the ADAPT+ extension study. Given the variability in how many treatment cycles each patient…
Despite treatment, people with myasthenia gravis (MG) in the U.S. continue to experience exacerbations — episodes of disease worsening that may require urgent treatment and hospitalization — that carry high clinical and economic costs. That’s according to a large retrospective analysis of claims data for patients with employer-based commercial…
An under-the-skin or subcutaneous injection formulation of efgartigimod has been approved in Japan for use by adults with generalized myasthenia gravis (gMG) who do not sufficiently respond to first-line treatment with steroids or non-steroidal immunosuppressive therapies. In Japan, the now-approved therapy — efgartigimod alfa and hyaluronidase-qvfc — will be…
TOL2, a medication being developed by Toleranzia for the treatment of myasthenia gravis (MG), was found to be well tolerated in a preclinical toxicology study, supporting the company’s decision to test it in humans. No side effects were observed when lab animals were given a dose of TOL2…
High levels of serum fibrinogen were found to be a sensitive and specific biomarker to identify people with myasthenia gravis (MG), according to a recent study. Fibrinogen is a plasma protein that participates in blood clotting and is usually not present in the serum. In MG patients, residual fibrinogen…
The European Commission has approved Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of certain adults with generalized myasthenia gravis (gMG), closely following its clearance of Zilbrysq (zilucoplan) as an add-on treatment last month. These medications are sold by the biopharma company UCB.
Treatment with the experimental cell therapy Descartes-08 led to reductions in disease severity that were sustained out to one year for five of seven generalized myasthenia gravis (gMG) patients taking part in a Phase 2a clinical trial. That’s according to new data, announced by the therapy’s developer Cartesian Therapeutics,…
Zilbrysq (zilucoplan), a new treatment for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR), is now commercially available in the U.S., with a list price likely to exceed $30,000 for a 30-day supply. Approved by the U.S. Food and…
In 2023, Myasthenia Gravis News brought up-to-date coverage of the latest scientific research and developments in the treatment of myasthenia gravis (MG). Here are the 10 most-read news stories of 2023, along with a brief description of what made them relevant for our readers. We look forward to…
Recent Posts
- Regaining control over life when MG weighs me down
- New US patient registry to track MG using real-world data
- Standard treatments don’t always work for triple-seronegative MG
- Exercise, breathing training may help ease myasthenia gravis symptoms
- I learn asking for help means choosing not to do everything the hard way